Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
727 gün önce
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
982 gün önce
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1009 gün önce
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1081 gün önce
U.S. Weekly Jobless Claims Edge Down To 229,000
A report released by the Labor Department on Thursday showed a modest decrease by first-time claims for U.S. unemployment benefits in the week ended August 23rd.
RTTNews
|
6 dakika önce
FTSE 100 Down 0.4% In Cautious Trade
After a slightly positive start, U.K. stocks turned weak Thursday morning with investors treading cautiously amid a lack of triggers. Shares of financials and utilities companies are struggling a bit.
RTTNews
|
1s 17 dakika önce
CAC Up Slightly; Pernod Ricard Rises On Earnings
The French market is up slightly a little past noon on Thursday, supported by data showing an increase in new car registrations in Europe, and stronger-than-expected results and forecast from AI chip major Nvidia.
RTTNews
|
1s 36 dakika önce
DAX Retreats After Firm Start, Down Marginally
After opening on a strong note thanks to easing AI slowdown fears after Nvidia's impressive results, the German market retreated and slipped into negative territory on Thursday. Despite paring some early gains, auto stocks remain fairly well up in positive territory.
RTTNews
|
1s 59 dakika önce
